Octapharma

Share
Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation in human protein therapies for over 25 years. Octapharma’s core business is the development, production, and sale of high-quality human protein therapies from both human plasma and human cell-lines.

Octapharma

 •  July 12

Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s active involvement includes two sponsored scientific symposia, one of which is dedicated to exploring recent data and real-world experiences with Nuwiq®,...

Octapharma

 •  May 22

Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally...

Octapharma

 •  March 1

The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015.

Octapharma achieved sales growth of 18.8% in North America, 14% in Eastern Europe and 6% in its well-established markets of Western Europe. The main contributors of the growth were...

Octapharma

 •  July 22, 2016

Lachen, Switzerland, July 22nd, 2016: Octapharma will sponsor a range of activities at this year’s WFH World Congress in Orlando, USA, including two symposia and a number of posters and scientific presentations highlighting Octapharma’s recent developments in haemophilia A and von Willebrand disease (VWD).
The first symposium, “Simple solutions to...

Octapharma

 •  January 20, 2016

Lachen, Switzerland, January 20th, 2016: Since 2011, Octapharma Australia has provided octaplasLG® (solvent/detergent treated human plasma) without cost to a young patient with C1q deficiency. OctaplasLG® is a pharmaceutically licensed product that includes manufacturing steps to remove/inactivate both viruses and prions.
C1q is one component of...

Octapharma

 •  September 19, 2015

Lachen, Switzerland, September 18th, 2015: Today Octapharma announced the recent publication in Haemophilia of data from the pivotal GENA-08 study, demonstrating outstanding success of their newest-generation human-cell-line recombinant human Factor VIII product, Nuwiq®, in prevention and treatment of bleeding episodes in adults with severe ...

Octapharma

 •  September 15, 2015

HOBOKEN, N.J. September 15th, 2015: Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved NUWIQ®, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The NUWIQ® approval includes on-demand treatment and control of bleeding episodes; routine prophylaxis to ...

Octapharma

 •  August 14, 2015

HOBOKEN, N.J. August 13th, 2015 – Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved revised product labeling for WILATE® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)] to include prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand ...

Octapharma

 •  July 13, 2015

LACHEN, Switzerland, July 13th, 2015 – Octapharma sponsored the symposium ‘Addressing complex issues in VWD & haemophilia care’ at the ISTH Congress in Toronto, Canada, on June 24th, 2015. The symposium, chaired by Professor Jerry Teitel (University of Toronto, Canada), provided an opportunity to discuss the complex issues in von Willebrand ...

Octapharma

 •  July 13, 2015

LACHEN, Switzerland, July 13th, 2015 – Octapharma sponsored the symposium ‘Haemophilia A: Individualised solutions to global challenges’ at the ISTH Congress in Toronto, Canada, on June 23rd, 2015. The symposium provided an opportunity to discuss the latest developments in haemophilia A treatment and the role of personalised care, with a focus on ...